Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
1.220
+0.050 (4.27%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Tharimmune Employees
As of December 31, 2024, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,065,856
Market Cap
2.57M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3 | 0 | - |
Dec 31, 2023 | 3 | 1 | 50.00% |
Dec 31, 2022 | 2 | 0 | - |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
THAR News
- 8 days ago - Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Accesswire
- 16 days ago - Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Accesswire
- 23 days ago - Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Accesswire
- 4 weeks ago - Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Accesswire
- 7 weeks ago - Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Accesswire
- 3 months ago - Tharimmune to Present at the Microcap Conference 2025 - Accesswire
- 4 months ago - Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Accesswire
- 4 months ago - Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Accesswire